We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · October 19, 2020

Pembrolizumab vs Pembrolizumab and Acalabrutinib in Patients With Platinum-Resistant Metastatic Urothelial Cancer

Cancer

 

Additional Info

Cancer
A Randomized Phase 2 Trial of Pembrolizumab Versus Pembrolizumab and Acalabrutinib in Patients With Platinum-Resistant Metastatic Urothelial Cancer
Cancer 2020 Oct 15;126(20)4485-4497, T Zhang, MR Harrison, PH O'Donnell, AS Alva, NM Hahn, LJ Appleman, J Cetnar, JM Burke, MT Fleming, MI Milowsky, A Mortazavi, N Shore, GP Sonpavde, EV Schmidt, B Bitman, V Munugalavadla, R Izumi, P Patel, J Staats, C Chan, KJ Weinhold, DJ George

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading